Tumor-infiltrating lymphocyte (TIL) score and PD-L1 expression in TME are previously suggested as potential biomarkers to select potentially sensitive subpopulation to ICB therapy prior to treatment and to predict survival for LUAD patients (Gascón et al., 2020; Jin et al., 2020; Hashemi et al., 2021). The gene discussed is CD274; the disease is neoplasm.